Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,251,802
  • Shares Outstanding, K 193,570
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 175 M
  • EBITDA $ 264 M
  • 60-Month Beta 0.67
  • Price/Sales 3.12
  • Price/Cash Flow 123.32
  • Price/Book 3.60

Options Overview Details

View History
  • Implied Volatility 30.78% ( -3.03%)
  • Historical Volatility 27.29%
  • IV Percentile 24%
  • IV Rank 24.58%
  • IV High 63.71% on 03/11/25
  • IV Low 20.05% on 06/26/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 1,539
  • Volume Avg (30-Day) 981
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 22,676
  • Open Int (30-Day) 19,688

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.13
  • Number of Estimates 9
  • High Estimate 1.26
  • Low Estimate 1.05
  • Prior Year -2.03
  • Growth Rate Est. (year over year) +155.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.51 +7.79%
on 05/23/25
71.29 -3.97%
on 06/16/25
+3.16 (+4.84%)
since 05/20/25
3-Month
53.56 +27.82%
on 04/09/25
71.29 -3.97%
on 06/16/25
+7.88 (+13.01%)
since 03/20/25
52-Week
53.56 +27.82%
on 04/09/25
83.95 -18.45%
on 11/08/24
+6.10 (+9.78%)
since 06/20/24

Most Recent Stories

More News
Private-Sector Oncology May Be the Market’s Best-Understood Secret

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer drug prices are rising sharply, with Bloomberg reporting growing concern over affordability and...

ONCY : 0.6901 (-6.74%)
INCY : 68.46 (+0.28%)
QGEN : 46.76 (+0.45%)
ONC.TO : 0.96 (-1.03%)
BMY : 46.86 (+0.04%)
BNTX : 106.53 (+2.04%)
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures...

SRPT : 20.08 (-3.32%)
ADI : 228.35 (-0.57%)
LVS : 41.68 (-0.24%)
SLB : 35.84 (-0.03%)
WYNN : 88.49 (+1.82%)
SAGE : 9.30 (+1.86%)
ELV : 374.52 (-0.37%)
OXY : 45.63 (+0.62%)
FANG : 148.85 (+0.05%)
AMD : 128.24 (+1.14%)
SPY : 594.28 (-0.23%)
NOC : 497.70 (+0.62%)
Stocks Rally as Iran Signals it Wants an End to Hostilities

The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are...

SRPT : 20.08 (-3.32%)
LVS : 41.68 (-0.24%)
SLB : 35.84 (-0.03%)
WYNN : 88.49 (+1.82%)
SAGE : 9.30 (+1.86%)
ELV : 374.52 (-0.37%)
OXY : 45.63 (+0.62%)
FANG : 148.85 (+0.05%)
AMD : 128.24 (+1.14%)
SPY : 594.28 (-0.23%)
UHS : 171.70 (+0.27%)
HCA : 377.50 (+0.17%)
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained

The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are...

AMAT : 169.46 (-1.96%)
ROKU : 80.99 (-0.54%)
AVGO : 249.99 (-0.51%)
KALV : 12.15 (-1.30%)
SRPT : 20.08 (-3.32%)
LVS : 41.68 (-0.24%)
WYNN : 88.49 (+1.82%)
SAGE : 9.30 (+1.86%)
$IUXX : 21,626.39 (-0.43%)
UNH : 302.01 (-1.69%)
ELV : 374.52 (-0.37%)
ZNU25 : 110-315s (+0.17%)
Regeneron Pharmaceuticals Stock: Is REGN Underperforming the Healthcare Sector?

Regeneron Pharmaceuticals has lagged behind the broader healthcare sector over the past year, still analysts are highly optimistic about the stock’s prospects.

XLV : 132.60 (-0.48%)
INCY : 68.46 (+0.28%)
REGN : 509.72 (-0.75%)
SNY : 47.86 (+0.50%)
Is Wall Street Bullish or Bearish on Incyte Stock?

Despite Incyte’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

BAC : 45.50 (+0.98%)
$SPX : 5,967.84 (-0.22%)
IBB : 125.51 (-0.21%)
INCY : 68.46 (+0.28%)
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte Corporation INCY reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.01. The company had recorded adjusted earnings of 58 cents per share...

BAYRY : 7.6800 (-1.16%)
LLY : 762.73 (-2.84%)
INCY : 68.46 (+0.28%)
NVS : 115.77 (-0.16%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 11.19 (+2.66%)
MTCH : 30.59 (+0.96%)
INCY : 68.46 (+0.28%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 11.19 (+2.66%)
MTCH : 30.59 (+0.96%)
INCY : 68.46 (+0.28%)
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY : 68.46 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 70.47
2nd Resistance Point 69.83
1st Resistance Point 69.15
Last Price 68.46
1st Support Level 67.82
2nd Support Level 67.18
3rd Support Level 66.49

See More

52-Week High 83.95
Fibonacci 61.8% 72.34
Fibonacci 50% 68.75
Last Price 68.46
Fibonacci 38.2% 65.17
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar